HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection

Fritz-Rdzanek
,Anna; Grzybowski,Wojciech; Beta,Jarosław; Durczyński,Andrzej; Jakimiuk,Artur

doi:10.3892/ol.2012.757

HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection

Authors:
- Anna Fritz-Rdzanek
- Wojciech Grzybowski
- Jarosław Beta
- Andrzej Durczyński
- Artur Jakimiuk
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Central Clinical Hospital of Ministry of Interior and Administration, 02-507 Warsaw, Poland
Published online on: June 13, 2012 https://doi.org/10.3892/ol.2012.757
Pages: 385-389

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer has the highest mortality of all gynecological cancers, and its progression is often without symptoms. Clinical outcome and survival may be improved if the disease is identified in the early stages. The objective of the study was to evaluate the utility of the serum biomarkers human epididymis protein 4 (HE4), soluble mesothelin-related protein (SMRP) and CA125 in the detection of ovarian cancer. In this retrospective study, the serum concentrations of CA125, HE4 protein and SMRP were measured in a cohort of 70 patients with epithelial ovarian cancer (EOC) compared with 78 healthy controls. Median serum levels of CA125 for ovarian cancer cases were 503.55±560.7 U/ml vs. 9.28±14.47 U/ml in the control group (p<0.001); for SMRP 5.13±7.64 nM vs. 1.02±0.89 nM (p<0.01); and for HE4 597.95±934.59 pM vs. 56.75±43.79 pM (p<0.001), respectively. Positive correlations between the clinical stage of EOC and CA125, HE4 and SMRP serum concentrations were found [(R=0.83; p<0.001); (R=0.64; p<0.001); (R=0.45; p<0.001), respectively]. Data analysis for the whole study group also revealed a significant correlation between plasma concentrations of CA125 and HE4 (R=0.45; p<0.001), between CA125 and SMRP (R=0.38; p<0.001) as well as HE4 and SMRP (R=0.51; p<0.001). Similar significant correlations between serum biomarker concentrations were also found in the ovarian cancer group [CA125 and HE4 (R=0.31; p<0.01); CA125 and SMRP (R=0.25; p<0.05); HE4 and SMRP (R=0.44, p<0.001), respectively]. A significant correlation was observed between the serous histological type of EOC and serum concentration of HE4 in the study group compared with other non-serous types of ovarian cancer (p<0.01). In conclusion, measuring CA125 in combination with new biomarkers such as SMRP and HE4 may improve the accuracy of ovarian cancer diagnosis, particularly in early detection of the disease.

View Figures

View References

1	Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin. 55:10–30. 2005.
2	Tortorelo-Luna G and Mitchell M: The epidemiology of ovarian cancer. J Cell Bioch. 23:200–207. 1995. View Article : Google Scholar
3	Gupta D and Lis C: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2:132003. View Article : Google Scholar : PubMed/NCBI
4	Lowe K, Shah C, Wallace E, et al: Effects of personal characteristics on serum CA125, mesothelin and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 17:2480–2487. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chu C and Rubin S: Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 20:307–320. 2002. View Article : Google Scholar
6	Canevari S, Gariboldi M, Reid J, et al: Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol. 60:19–37. 2006. View Article : Google Scholar : PubMed/NCBI
7	Gilks C, Ionescu D, Kalloger S, et al: Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 39(8): 1239–1251. 2008. View Article : Google Scholar
8	Pettersson F: Annual report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics; 1994
9	Lu K, Patterson A, Wang L, et al: Selection of potential markers of epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
10	Hoskins W: Prospective on ovarian cancer: why prevent? Cell Biochem Suppl. 23:189–199. 1995. View Article : Google Scholar : PubMed/NCBI
11	Pettersson F, Kolstad P, Ludwig H, et al: Annual report on the results of treatment in gynecological cancer. International Federation of Gynecology and Obstetrics. 1998.
12	Nguyen H, Averette H, Hoskins W, et al: National survey of ovarian carcinoma VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer. 72:3007–3011. 1993. View Article : Google Scholar
13	Bast RC Jr, Brewer M, Zou C, et al: Ovarian cancer prevention and early detection: mission impossible? Recent Results Cancer Res. 174:91–900. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zhang Z, Yu Y, Xu F, et al: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 107:526–531. 2007. View Article : Google Scholar : PubMed/NCBI
15	Havrilesky L, Whitehead C, Rubatt J, et al: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 110:374–382. 2008. View Article : Google Scholar : PubMed/NCBI
16	Scholler N, Crawford M, Sato A, et al: Bead-based ELISA assays for validation of ovarian cancer early detection markers. Clin Cancer Res. 1:2117–2124. 2006. View Article : Google Scholar : PubMed/NCBI
17	Nosov V, Feng S, Malaika A, et al: Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 200:639 e1–5. 2009.PubMed/NCBI
18	Oikonomopolou K, Li L, Zheng Y, et al: Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 99:1103–1113. 2008. View Article : Google Scholar : PubMed/NCBI
19	Pauler D, Menon U, McIntosh M, et al: Factors influencing serum Ca125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 10:489–493. 2001.PubMed/NCBI
20	Bast R and Knapp R: Use of CA125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur Obset Gyncol Reprod Biol. 19:354–356. 1995. View Article : Google Scholar
21	Fishman D: The present and future of biomarkers for the early detection of epithelial ovarian carcinoma. CME J Gynecol Oncol. 4:33–36. 1999.
22	Jacobs I and Bast R: The Ca125 tumor-associated antigen: a review of literature. Human Reprod. 4:1–12. 1989.
23	Wollas R, Xu F, Jacobs I, et al: Elevation of multiple serum markers in patients with stage I ovarian cancer. JNCI. 85:1748–1751. 1993. View Article : Google Scholar : PubMed/NCBI
24	Bast R: Status of tumor markers in ovarian cancer screening. J Clin Oncol. 21:200–205. 2003. View Article : Google Scholar : PubMed/NCBI
25	Skates S, Xu F, Yu H, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 76:2004–2010. 1995. View Article : Google Scholar : PubMed/NCBI
26	Shah C, Lowe K, Paley P, et al: Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4 and CA125. Cancer Epidemiol Biomarkers Prev. 18:1365–1372. 2009. View Article : Google Scholar : PubMed/NCBI
27	Jacobs I and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
28	Palmer C, Duan X, Hawley S, et al: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 3:e26332008. View Article : Google Scholar : PubMed/NCBI
29	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
30	Chang K, Pai LH, Batra JK, et al: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 52:181–186. 1992.PubMed/NCBI
31	Blaustein A: Peritoneal mesothelium and ovarian surface cells-shared characteristics. Int J Gynecol Pathol. 3:361–375. 1984.PubMed/NCBI
32	Okamura H, Katabuchi H, Nitta M, et al: Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology. Microsc Res Tech. 69:469–481. 2006. View Article : Google Scholar : PubMed/NCBI
33	Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9:1191–1197. 2008. View Article : Google Scholar : PubMed/NCBI
34	Okamura H: Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability. Ital J Anat Embryol. 106(Suppl 2): 263–276. 2001.PubMed/NCBI
35	Kurman RJ and Shih IM: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
36	McIntosh M, Drescher C, Karlan B, et al: Combining CA125 and SMRP serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 95:9–15. 2004. View Article : Google Scholar : PubMed/NCBI
37	Scholler N, Garvik B, Hayden-Ledbetter M, Kline T and Urban N: Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 247:130–136. 2007. View Article : Google Scholar : PubMed/NCBI
38	Drapkin R, Von Horsten H, Lin Y, et al: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005. View Article : Google Scholar : PubMed/NCBI
39	Galgano M, Hampton G and Frierson H: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
40	Hellström I, Raycraft J, Hayden-Ledbetter M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
41	Moore R, Brown A, Miller C, et al: Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. J Clin Oncol. 24:18S2006.
42	Berry N, Cho Y, Harrington M, et al: Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol. 92:896–904. 2004. View Article : Google Scholar : PubMed/NCBI
43	Moore R, Brown A, Miller M, et al: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 108:402–408. 2007. View Article : Google Scholar : PubMed/NCBI
44	Moore R, McMeekin D, Brown A, et al: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
45	Pauler D, Menon U, McIntosh M, et al: Factors influencing serum CA125II levels in healthy postmenopausal woman at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 17:2480–2487. 2008. View Article : Google Scholar
46	Hellström I, Raycraft J, Kanan S, et al: Mesothelin variant I is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarker Prev. 15:1014–1020. 2006.PubMed/NCBI
47	Das P and Bast R Jr: Early detection of ovarian cancer. Biomark Med. 2:291–303. 2008. View Article : Google Scholar
48	Köbel M, Kalloger S, Boyd N, et al: Ovarian carcinoma subtypes are different diseases: implication for biomarker studies. PLoS Med. 5:e2322008.PubMed/NCBI
49	Kozak K, Su F, Whitelegge J, et al: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI